
The FDA has issued new draft guidance on how pharmaceutical and medical device firms in the US can talk about …

NICE needs to be reformed with its QALY formula heavily revised if it is to meet the challenges of 21st …

Pharmaxis Pharmaceuticals has been given the most severe punishment that the PMCPA can hand out following a series of breaches …

Novo Nordisk has been cleared completely of any wrongdoing over a complaint about three of its employees in relation to …

The use of ‘extravagant’ dinners and ‘excessive alcohol’ has landed Merck Serono in hot water with the PMCPA as it’s …
The ABPI has appointed David Watson as its new head of Commercial, who will be reporting to the association’s Commercial …

There has been considerable publicity over the last year or two about transparency of information in clinical trials. However, activity …

The ABPI has appointed Christine Rowland to the newly-created position of value and access manager for its commercial department. Rowland …

Jonathan Emms, UK managing director of Pfizer, has taken up his appointment as president of the ABPI, after his election …

The UK healthcare system is at risk of failing to adopt new, personalised medicines and must be willing to pay …

Europe took a decisive step toward forcing pharma to open up its clinical trial data last night, after the EU …

Allergan has been found guilty of breaching six clauses of the ABPI’s Code of Practice over its market research for …

The ABPI has once again voiced concern that NHS patients in some areas of England are not getting access to …

The first payments in pharma’s new pricing deal with the Department of Health are to be made this month as …

Half of all trials registered on a US clinical study database are not being published in public journals. This is …